Striatonigral degeneration
ICD-10 G23.2 is a billable code used to indicate a diagnosis of striatonigral degeneration.
Striatonigral degeneration is a rare neurodegenerative disorder characterized by the progressive degeneration of the striatum and substantia nigra, which are critical components of the basal ganglia involved in the regulation of movement. This condition is classified under the category of atypical parkinsonian syndromes, which exhibit symptoms similar to Parkinson's disease but have distinct pathological features. Patients typically present with a combination of parkinsonism, including bradykinesia, rigidity, and postural instability, along with additional symptoms such as dysarthria, dysphagia, and cognitive decline. Unlike classic Parkinson's disease, striatonigral degeneration may also lead to significant autonomic dysfunction and a more rapid progression of symptoms. The underlying pathophysiology involves the accumulation of abnormal proteins and neuronal loss, particularly affecting dopaminergic pathways. Diagnosis is primarily clinical, supported by neuroimaging findings that may reveal atrophy of the striatum. Management often includes dopaminergic medications, although their efficacy may be limited compared to traditional Parkinson's disease treatments. As the disease progresses, patients may require comprehensive care, including physical therapy and supportive services.
Detailed neurological examination findings, imaging results, and treatment response.
Diagnosis of atypical parkinsonism, management of motor symptoms, and cognitive assessments.
Ensure clear documentation of symptom onset and progression to support the diagnosis.
Comprehensive assessment of functional status and comorbidities.
Management of elderly patients with movement disorders and cognitive decline.
Consideration of polypharmacy and its impact on treatment outcomes.
Used for follow-up visits for patients with striatonigral degeneration.
Document history, examination findings, and treatment plan.
Neurologists should focus on neurological assessments and medication management.
Primary symptoms include bradykinesia, rigidity, dysarthria, dysphagia, and cognitive decline, often progressing rapidly compared to typical Parkinson's disease.
